<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The G380R mutation in the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) causes <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e>, the most common form of human <z:hpo ids='HP_0003510'>dwarfism</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Achondroplasia</z:e> is a heterozygous disorder, and thus the affected individuals express both <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant FGFR3 </plain></SENT>
<SENT sid="2" pm="."><plain>Yet heterodimerization in <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> has not been characterized thus far </plain></SENT>
<SENT sid="3" pm="."><plain>To investigate the formation of FGFR3 heterodimers in cellular membranes, we designed an FGFR3 construct that lacks the kinase domain, and we monitored the formation of inactive heterodimers between this construct and <z:mp ids='MP_0002169'>wild-type</z:mp> and mutant FGFR3 </plain></SENT>
<SENT sid="4" pm="."><plain>The formation of the inactive heterodimers depleted the pool of full-length receptors capable of forming active homodimers and ultimately reduced their phosphorylation </plain></SENT>
<SENT sid="5" pm="."><plain>By analyzing the effect of the truncated FGFR3 on full-length receptor phosphorylation, we demonstrated that FGFR3 WT/G380R heterodimers form with lower probability than <z:mp ids='MP_0002169'>wild-type</z:mp> FGFR3 homodimers at low ligand concentration </plain></SENT>
<SENT sid="6" pm="."><plain>These results further our knowledge of FGFR3-associated <z:e sem="disease" ids="C0005940" disease_type="Disease or Syndrome" abbrv="">bone disorders</z:e> </plain></SENT>
</text></document>